Research and Development Expenses Breakdown: Amgen Inc. vs GSK plc

Amgen vs GSK: A Decade of R&D Investment Trends

__timestampAmgen Inc.GSK plc
Wednesday, January 1, 201442970000003450000000
Thursday, January 1, 201540700000003560000000
Friday, January 1, 201638400000003628000000
Sunday, January 1, 201735620000004476000000
Monday, January 1, 201837370000003893000000
Tuesday, January 1, 201941160000004568000000
Wednesday, January 1, 202042070000005098000000
Friday, January 1, 202148190000005278000000
Saturday, January 1, 202244340000005488000000
Sunday, January 1, 202347840000006223000000
Monday, January 1, 20245964000000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: Amgen Inc. vs GSK plc

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and GSK plc have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, GSK plc's R&D expenses surged by approximately 80%, peaking in 2023 with a 6.2 billion USD investment. This reflects GSK's aggressive push towards expanding its research capabilities and product pipeline.

Conversely, Amgen Inc. maintained a more stable R&D expenditure, with a modest increase of around 11% over the same period. Their highest investment was recorded in 2021, with a 4.8 billion USD allocation. This steady approach underscores Amgen's focus on optimizing existing research avenues while cautiously exploring new opportunities. As these giants continue to innovate, their R&D strategies will undoubtedly shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025